Retail News Breaks Archives
CVS adds to Pharmacy Advisor program
February 7th, 2013
WOONSOCKET, R.I. – CVS Caremark Corp. has expanded its Pharmacy Advisor medication management program to cover five more chronic conditions
CVS said Thursday that the program can now assist pharmacy patients taking medications for asthma, breast cancer, chronic obstructive pulmonary disease (COPD), depression and osteoporosis.
Previously, Pharmacy Advisor had focused on patients with diabetes or cardiovascular conditions. The medication adherence program, launched in mid-2010, has conducted more than 3.8 million interventions to date.
Under the condition-based program, pharmacists are alerted when patients don't follow their medication regimens or have a gap in care, enabling the pharmacist to intervene with patients and communicate with their doctors in real time.
"We are delighted to extend Pharmacy Advisor and its benefits to patients managing medications associated with additional chronic conditions," Troy Brennan, executive vice president and chief medical officer of CVS Caremark, said in a statement. "Pharmacists play an important role in the coordination of care for individuals living with chronic conditions and understand how critical medication adherence is in supporting their patients."
CVS noted that by fostering pharmacist interventions, Pharmacy Advisor increases patient engagement and, in turn, reins in medical costs because of improved compliance with medications. The program, too, directs members with chronic conditions to disease management programs where they can get further support.
"Pharmacy Advisor not only improves quality of care for individuals with chronic conditions by providing an additional layer of support, it also addresses the important systemic challenges of health care costs related to medication nonadherence," stated Jon Roberts, president of CVS Caremark's pharmacy benefit management business. "Extending the program to cover a broader range of chronic conditions expands our ability to support even more patients on their path to better health, while reducing the burden of cost associated with medication nonadherence for patients with these conditions."